Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2008 Results
Date:1/29/2009

research costs.

The company recognized a charge of $4.685 billion in the fourth quarter of 2008 for acquired in-process research and development associated with the acquisition of ImClone Systems. In the fourth quarter of 2007, the company recognized a charge of $89.0 million for acquired in-process research and development associated with the MacroGenics and Glenmark in-licensings.

The company recognized asset impairments, restructuring, and other special charges of $80.0 million in the fourth quarter of 2008. In the fourth quarter of 2007, the company recognized asset impairments, restructuring, and other special charges of $98.2 million.

Other income decreased by $113.3 million, to a net expense of $81.2 million, primarily due to a $47.6 million net loss on investment securities (the majority of which are unrealized) and higher interest expense associated with the ImClone acquisition.

The company recognized income tax expense of $292.0 million in the fourth quarter of 2008 despite having a loss before income taxes of $3.337 billion. The company's net loss for the fourth quarter was driven by the $4.685 billion in-process research and development charge for ImClone. The in-process research and development charge was not tax deductible. In addition, the company recorded tax expense associated with the ImClone acquisition, as well as a discrete income tax benefit of $136.9 million in the fourth quarter of 2008, which was associated with the EDPA settlement recorded in the third quarter of 2008. The effective tax rate was 18.8 percent in the fourth quarter of 2007.

Primarily as a result of the ImClone acquisition charges, on a reported basis the company recorded a net loss of $3.629 billion, or $3.31 per share in the fourth quarter of 2008, compared with fourth-quarter 2007 net income of $854.4 million and earnings per share of $.78.

On a non-GAAP basis, net in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide and ... from legally blind to perfect 20/20 vision has caught the ... “There is a huge portion of the population today that ... people just think that’s the way it will always be ... pretty risky at times,” reports Michaels. “This program is a ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... DENVER For the first time an oncogenic somatic ... during transfection) protein has been identified in small cell ... mutation within SCLC cell lines produced increased intracellular signaling ... form of lung cancer representing 15% of all lung ... representing 85% of lung cancer, has been extensively examined ...
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... in two years, California researcher says , , FRIDAY, Feb. 1 ... the progress of the disease in 90 percent of the ... turned the cancer into a chronic, manageable disease," said W. ... Feb. 1 issue of Cancer Research . , Twenty ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... 1 Lifespring Health,sponsors the Kaiser Permanente San Francisco ... charity event benefiting the Hemophilia Foundation of,Northern California, Support ... House., Set to take place on Feb. 3, ... course is ranked as one of the most scenic,in ...
... Piwek to Assist in Generating New Retail Licensing ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), a ... patented dermatology,products with their proprietary polymer delivery system ... selected as a new member of,the Company,s Board ...
... and vigilance show a relationship with core body temperature ... high during the daytime, skin temperature is low, which ... temperature is low at night time, skin temperature is ... suffering from narcolepsy, however, direct manipulations of their skin ...
... , UCLA and University of North Carolina researchers have found ... sexual and/or physical abuse may have a heightened brain response ... IBS is a condition that affects 10 to 15 percent ... constipation or both. , Researchers used brain ...
Cached Medicine News:Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)...  - MediaLINC unlocks the real ... general availability of MediaLINC - its innovative ... education, entertainment and clinical content direct to standard HD ... " Lincor has already been phenomenally ... bedside smart devices, " comments Dan Byrne , ...
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... ("CTI") (NASDAQ and MTA: CTIC) announced today the results from ... 2011. At the meeting, shareholders approved the proposal to amend ... total number of authorized shares and authorized shares of common ... Headquartered in Seattle, CTI is a biopharmaceutical ...
... June 17, 2011 The St. Francis Heart Center ... first post-FDA approval surgery in the United States using a new ... Contour 3D™ Annuloplasty Ring, the device, which is manufactured by ... the natural valve,s shape and size. The procedure ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 3
... Introducing the new PRONEB® ULTRA compressor. This ... time while delivering more medication to the ... LC PLUS® or PARI LC STAR® Reusable ... optimized for inhalation and retention into the ...
... PRONEB® ULTRA compressor. This high output compressor ... more medication to the patient's lungs. When ... PARI LC STAR® Reusable Nebulizer, the particle ... and retention into the lungs. With less ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
... Air., ,Allied Healthcares Timeter® PCS 414 portable ... air compressors that you may wonder if its ... 414 features a durable, mar-resistant steel case thats ... weighs only 26.5 pounds. The PCS 414 has ...
Medicine Products: